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Abstract
Introduction: Analysis of sequence data in high-risk pedigrees is a powerful approach
to detect rare predisposition variants.
Methods: Rare, shared candidate predisposition variants were identified from
exome sequencing 19 Alzheimer’s disease (AD)-affected cousin pairs selected from
high-risk pedigrees. Variants were further prioritized by risk association in various
external datasets. Candidate variants emerging from these analyses were tested for
co-segregation to additional affected relatives of the original sequenced pedigree
members.
Results: AD-affected high-risk cousin pairs contained 564 shared rare variants.
Eleven variants spanning 10 genes were prioritized in external datasets: rs201665195
(ABCA7), and rs28933981 (TTR) were previously implicated in AD pathology;
rs141402160 (NOTCH3) and rs140914494 (NOTCH3) were previously reported;
rs200290640 (PIDD1) and rs199752248 (PIDD1)werepresent inmore thanone cousin
pair; rs61729902 (SNAP91), rs140129800 (COX6A2, AC026471), and rs191804178
(MUC16) were not present in a longevity cohort; and rs148294193 (PELI3) and
rs147599881 (FCHO1) approached significance from analysis of AD-related pheno-
types. Three variants were validated via evidence of co-segregation to additional rela-
tives (PELI3, ABCA7, and SNAP91).
Discussion: These analyses support ABCA7 and TTR as AD risk genes, expand on pre-
viously reported NOTCH3 variant identification, and prioritize seven additional candi-
date variants.
KEYWORDS
ABCA7, Alzheimer’s disease, genetic analysis, high-risk pedigree, NOTCH3, rare variant analysis,
TTR, Utah Population Database, whole exome sequence
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1 INTRODUCTION
Genetic variation significantly impacts Alzheimer’s disease (AD) risk
and is estimated to account for 53% of total trait variance.1 To date,
genome-wide association studies (GWAS) for AD have identified com-
monvariants occurring inmore than30 genes.1,2 Despite this progress,
it is estimated that more than 40% of the genetic variance of AD
remains uncharacterized.3 While rare variation contributing to AD
is difficult to detect via GWAS, it may be discoverable in pedigree-
based designs. It is well recognized that high-risk pedigree studies are
a powerful and efficient method for identification of rare predisposi-
tion variants and should be performed when these rare resources are
available.4–6 Pedigree-based studies are ideal for rare variant identi-
fication because rare variants can occur at a higher-than-population
rate among related affected individuals, thereby enhancing statisti-
cal power.7,8 Additionally, pedigree analyses limit locus heterogeneity
(i.e., different gene loci or gene loci interactions causing a similar phe-
notype) because the rare variants are inherited by a common ances-
tor with a common haplotype. Although familial locus heterogeneity
may exist, the success rate at identifying causal variants in large pedi-
grees can be much higher than in clinical settings.9 Pedigree-based
designs have been successfully applied to gene discovery for many
phenotypes10–12 including AD, where notable examples are PLD3,13
NOTCH3,14 and RAB10.15 Here, a pedigree-based analysis using exome
sequences from 19 AD-affected cousin pairs belonging to pedigrees
with a statistical excess of AD mortality was performed to identify
genetic variants associated with AD risk. Candidate variants arising
from this analysis were then further prioritized in publicly available,
large-scale datasets to further evaluate their risk of AD. Prioritized
variants were then tested for co-segregation in additional previously
sampled relatives of the index cousin pairs.
2 MATERIAL AND METHODS
2.1 Utah Population Database (UPDB)
The UPDB includes a genealogy of Utah, representing the founders in
the mid-1800s to their modern-day descendants. It originated from
three-generation genealogy records16 and is kept current with Utah
vital statistics data, which includes approximately 50,000 largely unre-
lated founders of European descent. More than three million indi-
viduals with at least three generations of genealogy connecting to
Utah founders in the UPDB were analyzed here. The UPDB has been
linked to various phenotypic data including the Utah Cancer Reg-
istry from 1966 and Utah death certificates from 1904 to 2014.
This unique combination of genealogy with phenotypes has con-
tributed to the identification, recruitment, consent, and sampling of
over 30,000 individuals in thousands of high-risk pedigrees represent-
ing many disorders. Previous analyses of the UPDB genealogy have
reported that founder effects are not present among the Utah popu-
lation and indicate low inbreeding levels similar to other places in the
United States.17,18
RESEARCH INCONTEXT
1. Systematic review: Despite recent advances in identify-
ing common genetic variants associated with Alzheimer’s
disease (AD), it is estimated that more than 40% of the
genetic variance of AD remains uncharacterized. High-
risk pedigree studies offer more statistical power for
identification of rare predisposition variants, and they
have previously been used to identify variants in PLD3,
NOTCH3, and RAB10.
2. Interpretation: Pedigree-based analyses using exome
sequences from 19 AD-affected cousin pairs with
extended segregation assays were performed. These
analyses add support to ABCA7 and TTR as AD risk
genes. Furthermore, seven other candidate variants are
prioritized in addition to NOTCH3 variants that were
previously reported.
3. Future directions: Our analyses provide support for rare
variant prioritization through pedigree-based analyses.
Additional inquiries into ABCA7 and TTR as AD risk genes
are warranted. Moreover, these analyses suggest rare
variants in NOTCH3, PIDD1, SNAP91, COX6A2, MUC16,
PELI3, and FCHO1may contribute to AD risk.
2.2 Identification of sampled high-risk AD
mortality pedigrees
Among the individualswith storedDNA fromUtah pedigreeswere 199
subjects whose death certificates indicated AD as a cause of death.
These 199 individuals were related in 102 independent, descending
pedigrees including between two and six sampled AD mortality cases.
Each pedigree was tested for an excess of AD deaths among descen-
dants as described elsewhere.15using all available genealogy and death
certificate data. Twenty-four high-risk pedigrees including two to four
sampled AD cases were identified. Of those pedigrees, 19 unrelated
pedigreeswere selected for this analysis that includedat least one sam-
pledAD-affected approximate-cousin pair, ranging in relationship from
avuncular (n = 1; expected shared DNA = 25%) to third cousin (n = 1;
expected shared DNA= 0.78%).
2.3 Exome sequencing of AD cousin pairs
TwoAD-affected cousins from each of the 19 high-risk pedigrees were
exome sequenced at the Huntsman Cancer Institute’s Genomics Core
Facility. The Agilent SureSelect XT Human All Exon + UTR (v5) cap-
ture kit was used to prepare the DNA library from 2 μg of DNA per
sample. Paired-end reads of up to 150 base pairs were sequenced on
the IlluminaHiSeq2000 sequencer. BWA-MEM19,20 mapped rawreads
to the human genome v37 (GRCh37) reference genome. The Genome
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Analysis Toolkit 3.5.0 (GATK)21 software called variants using the
Broad Institute’s best practices guidelines. Variants were removed if
they occurred outside the exon capture kit intended area of coverage,
and the remaining variantswere annotatedwithANNOVAR22 for their
predicted pathogenicity.
Pathogenicity predictions were conducted in ANNOVAR using
various algorithms because deleterious predictions made by mul-
tiple prediction methods are more likely to be reliable.23 Table S1
in supporting information shows scores reported by SIFT,24,25
Polyphen-2,26 LRT,23 MutationTaster2,27 FATHMM,28 PROVEAN,29
VEST3,30 MetaSVM, MetaLR, M-CAP,31 REVEL,32 CADD,33 DANN,34
EIGEN,35 GenoCanyon,36 and GERP++.37 Prioritized variants were
predicted to be deleterious by at least two of those functional
prediction algorithms.
2.4 The Alzheimer’s Disease Genetics Consortium
Dataset
Some variant prioritization (described below) was based on compar-
isons to theAlzheimer’sDiseaseGeneticsConsortium (ADGC) dataset.
ADGC contains imputed single-nucleotide polymorphism (SNP) array
data for 28,730 subjects (11,967 males and 16,760 females), includ-
ing 10,486 AD cases and 10,168 healthy controls. Of the shared rare
exonic variants in the cousin pairs, 291 were sequenced or imputed in
the ADGC dataset.
2.5 The Knight cerebrospinal fluid dataset
The Knight Alzheimer’s Disease Research Center at Washington Uni-
versity School of Medicine (Knight ADRC) cerebrospinal fluid (CSF)
dataset was used for analyses of association between candidate vari-
ants and levels of AB42, Tau, or PTau. This cohort consisted of 3963
subjects (1895 males and 1675 females), including 1479 AD cases and
1370 healthy controls. All samples were genotyped using the Illumina
610 or OmniExpress chip. Of the shared rare variants in the cousin
pairs, only 12 appeared in the Knight ADRC dataset. Additional impu-
tation on the Knight ADRC dataset would likely lead to a higher false
discovery rate because rare variant imputation is much less accurate
than common variant imputation.38 Therefore, those 12 variants were
used only for additional variant prioritization on the rare variants iden-
tified in the high-risk pedigrees.
2.6 Wellderly dataset
The Wellderly study39 is an ongoing study that includes elderly peo-
ple (age 80–105) who are cognitively healthy without medical inter-
ventions. Six hundred Wellderly individuals had their whole genomes
sequenced using the Complete Genomics platform. These genomes
were used to perform additional variant prioritization because func-
tionally relevant rare genetic variants associatedwithADshouldnotbe
present in an elderly population that does not exhibit cognitive decline.
2.7 Assessing common genetic variants
Polygenic risk scores for each cousin were calculated and compared to
ADGC cases and controls to ensure that the excess risk for ADwas not
caused by an excess of common disease-associated variants (see Note
S1 in supporting information). The AD polygenic risk scores calculated
from Lambert, Ibrahim-Verbaas,2 and apolipoprotein E (APOE) geno-
type for each cousin are shown in Table S2 in supporting information. A
Welch’s two-sample t-test shows that the mean AD risk from common
variants in the high-risk cousin pairs is significantly less than the mean
AD risk for ADGC cases (P-value= 2.836 × 10−9; see Figure S1 in sup-
porting information) and controls (P-value = 9.486 × 10−4; see Figure
S2 in supporting information). Therefore, the propensity of AD in these
high-risk pedigrees is likely caused by rare genetic variants that can be
prioritized using the pipeline shown below.
2.8 Initial variant prioritization
Candidate variants were initially required to be present in both AD-
affected cousin pairs from at least 1 of the 19 high-risk AD pedigrees.
Further analysis in Ingenuity Variant Analysis software (QIAGEN, Inc.)
ensured variants were rare by removing variants with a population
minor allele frequency (MAF) greater than 0.01 in 1000 Genomes,40
Exome Aggregation Consortium (ExAC) non-Finnish European,41 The
Genome Aggregation Database (gnomAD),41 and NHLBI GO Exome
Sequencing Project (ESP), Seattle, WA (http://evs.gs.washington.edu/
EVS/) [March 2018].
Ingenuity Variant Analysis then prioritized variants based on their
predicted pathogenicity. Variants considered “Pathogenic,” “Likely
Pathogenic,” or “Unknown” by theAmericanCollege ofMedical Genet-
ics (ACMG),42 or resulted in either a loss or gain of gene function by in
silico functional prediction algorithmswere prioritized.
2.9 Prioritization in external datasets
Four distinct strategies were used to further prioritize candidate vari-
ants in external datasets related to AD. Each strategy was evaluated
independently of the others. Variants thatmet any one of these criteria
were prioritized as candidate variants for AD. Variants were assumed
to be likely causing the excess of AD mortality in the pedigrees if they
were (1) a known AD risk variant, (2) a CSF biomarker of AD with a P-
value less than .1, (3) not present in the Wellderly dataset and more
prevalent in ADGC AD cases than ADGC controls, or (4) observed in
more than one AD-affected cousin pair, as described below.
2.9.1 Known AD risk variant
A literature search of all shared rare variants was conducted in Inge-
nuity Variant Analysis to determine the extent to which these vari-
ants were previously implicated in AD pathology, indicating additional
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support from independent studies. Variants with publications support-
ing their association with ADwere prioritized.
2.9.2 Increased AD risk in CSF dataset
Three linear regressionswere conductedon theKnightADRCCSFdata
using PLINK43: one for each of the phenotypes of interest (AB42, Tau,
andPTau), with age,APOE status, sex, and twoprincipal components2,44
as covariates. The threshold for prioritizing candidate variants was
P-value less than .1 for any of the three phenotypes. The significance
threshold was relaxed because variants had a low minor allele fre-
quency and a small sample size.
2.9.3 AD risk gradient
Variants positively affecting AD mortality are expected to be more
prevalent in diseased elderly cohorts than healthy elderly cohorts. The
Wellderly dataset was used to ensure that prioritized variants were
not present in a healthy longevity cohort. Furthermore, the MAF of
the variant in ADGC controls needed to be less than or equal to the
MAF in ADGCAD cases to ensure that the variant wasmore prevalent
in AD cases than controls.
2.9.4 Multiple hit pedigrees
Variants that were identified inmore than one AD-affected cousin pair
were also prioritized as candidates. This prioritization provided addi-
tional evidence for the candidate variant as a potential AD risk fac-
tor because of its prevalence in AD subjects from multiple high-risk
pedigrees. Because all variants analyzed in this study are rare variants
(MAF<0.01), it is not likely that the same rare variantwouldbepresent
in two independent pedigrees and shared by both affected cousins by
random chance.
2.10 Evidence for segregation with AD risk in
additional affected sampled relatives
A set of 199 individuals previously sampled for Utah high-risk dis-
ease studies whose Utah death certificate included AD as a cause of
death and had at least three generations of genealogy linking to Utah
founders, was assayed for 9 of the 11 variants. An assay was not avail-
able for PIDD1 rs200290640, and the assay for PIDD1 rs199752248
failed due to too many homologous regions in the genome to specify
the right location. The AD cases from all affected cousin pairs were
included, and all assays correctly identified the observed carriers for
eachof thenine candidate variants. Evidenceof co-segregation to addi-
tional affected relatives was evaluated with the RVsharing program.45
The RVsharing calculates the probability of an observed configuration
of carriers and affection status in a pedigree having occurred by chance
transmission, assuming that the variant is rare (MAF < 0.01) and has
entered the pedigree only once. The RVsharing program provides a
test of co-segregation (e.g., linkage) in which the strength of evidence
against the null hypothesis of no co-segregation between the disease
and a variant is expressed as an exact probability (P-value) for a given
pedigree structure and disease configuration. Because the pedigrees
werepre-screened for a statistical excess ofAD, rare variants thatwere
shared among the related individuals likely contribute to the excess




Initial variant prioritization of rare variants shared by at least one
cousin pair identified 400 rare variants spanning 470 genes. Ingenu-
ity Variant Analysis subsequently prioritized 382 variants in 447 genes
thatwerepathogenic, likely pathogenic, uncertain significance, or asso-
ciated with a gain or loss of gene function. Of those shared rare vari-
ants, 117 variants in 138 genes had a biological interaction with genes
implicated in AD. The numbers of variants included after each analy-
sis are shown in Figure 1, and each variant is listed in File S1 in sup-
porting information. That list of 117 variants was then used by four
independent prioritization screens to identify 11 rare variants span-
ning10geneswith the strongest support for increasingADrisk in these
high-risk pedigrees (see Table 1). Four rare variants previously associ-
ated with increased AD risk were identified using a literature search
in Ingenuity Variant Analysis. The Knight ADRC CSF dataset identi-
fied two additional variants (Note: of the 117 prioritized variants, only
11 appeared in the CSF dataset) that were associated with increased
risk for AB42, Tau, or Ptau in CSF. Additionally, the AD Risk Gradi-
ent identified three variants that were not present in the Wellderly
dataset and were more prevalent in ADGC cases than ADGC controls.
Finally, two variants were present in two independent high-risk AD
pedigrees.
3.2 Evidence for co-segregation with AD risk in
additional affected sampled relatives
Five candidate variants assayed for segregation evidence had no
additional carriers beyond the original cousin pair, including: MUC16
rs191804178, NOTCH3 rs141402160, NOTCH3 rs140914494, FCHO1
rs147599881, and COX6A2 rs140129800. An additional carrier was
identified among the 199 assayed AD cases for TTR rs28933981, but
the additional carrier was not related to the original AD-affected
cousin pair sharing the variant. Additional related AD-affected carri-
ers were observed among the 199 assayed cases for four of the nine
assayed candidate variants. The other five newly identified AD case
carriers were not related to any of the other carriers or to each other.
Five AD-affected carriers were observed for PELI3 rs148294193,
including the original cousin pair. One of the newly identified case
carriers was a cousin (and avuncular) to the original cousin pair (rare
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F IGURE 1 Flowchart depicting variant prioritization. The number of rare variants and genes remaining at each level are shown. ADRC,
Alzheimer’s Disease Research Center; CSF, cerebrospinal fluid; MAF, minor allele frequency.
variant sharingP-value= .006), and theother twonewly identified case
carriers were unrelated to all other carriers. Four AD-affected carriers
were observed for ABCA7 rs201665195 including the original cousin
pair. One of the newly identified case carriers was a sibling to one of
the original cousin carriers (rare variant sharing P-value = .027), and
one carrier was not related to any other carriers. Three AD-affected
carriers were observed for SNAP91 rs61729902, including the original
cousin pair. The newly identified case carrier was a sibling of one of the
original cousins (rare variant sharing P-value= .027).
4 DISCUSSION
Analysis of exomes from 19 AD-affected cousin pairs identified 400
shared rare candidate AD predisposition variants. Initial prioritization
with Ingenuity Variant Analysis on likely pathogenicity and biological
context reduced this list to 117 rare variants occurring in 138 genes.
Further prioritization in one of four independent datasets, further pri-
oritized 11 variants in 10 genes (Table 1). Four of these variants in
three genes (ABCA7, TTR, and NOTCH3) represent replications of pre-
vious associations to AD, while the remaining eight variants are better
classified as candidate variants still requiring validation, although each
exhibited some level of replication throughoneof the four independent
prioritization strategies. Finally, variants in ABCA7, SNAP91, and PELI3
showed significant evidence of segregation to other related AD cases
in the high-risk pedigrees in which they were identified.
Four identified rare variants were previously reported in the lit-
erature as associated with increasing AD risk (known AD risk vari-
ants). The first variant, NM_019112.3:c.302T > G (rs201665195), is
found in the ABCA7 gene on chromosome 19. Unfortunately, this
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TABLE 1 Prioritized variants
Accession number Gene HGVS variant Impact Final prioritization
rs201665195 ABCA7 NM_019112.3:c.302T>G Missense KnownAD risk variant46,47
rs28933981 TTR NM_000371.3:c.416C> T Missense KnownAD risk variant48
rs141402160 NOTCH3 NM_000435.3:c.743G>C Missense KnownAD risk variant (reported using
these pedigrees in Patel et al.49)
rs140914494 NOTCH3 NM_000435:c.593C> T Missense KnownAD risk variant (reported using
these pedigrees in Patel et al.49)
rs148294193 PELI3 NM_001243135.1:c.115G>C Missense CSF biomarker P-value= .0553
rs147599881 FCHO1 NM_001161357.1:c.557G>A Missense CSF biomarker P-value= .0624
rs61729902 SNAP91 NM_00124279.1:c.2113C> T Missense AD risk gradient
rs140129800 COX6A2 NM_005205.3:c.34T>G Missense AD risk gradient
rs191804178 MUC16 NM_024690.2:c.10900C> T Missense AD risk gradient
rs200290640 PIDD1 NM_145886.3:c.2044C> T Missense Prioritized inmultiple pedigrees
rs199752248 PIDD1 NM_145886.3:c.2042-2A>G Splicing (intronic) Prioritized inmultiple pedigrees
Notes: These variants are most likely to affect AD pathology in the high-risk pedigrees. The accession number, affected gene, the Human Genome Variation
Society (HGVS) variant annotation, impact on translation, and the final prioritization option that identified the variant are shown.
Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid.
variant was not included in the ADGC validation datasets, so it could
not be independently validated beyond the cousin pairs. Le Guennec
et al.46 observed this variant, along with other rare ABCA7 variants,
in AD cases and confirmed that rare, loss of function, and predicted
damaging missense variants in ABCA7 are more common in patients
with AD. Vardarajan et al.47 also identified this rare variant in two
of their three late-onset AD (LOAD) cohorts, and this variant was
not seen in unaffected individuals. The cousin pairs analysis, and evi-
dence for segregation, adds additional support toABCA7 as a gene that
impacts AD.
Variant NM_000371.3:c.416C > T (rs28933981) is located in the
TTR gene on chromosome 18. Although this variant was sequenced in
the ADGC validation datasets, it did not pass quality control thresh-
olds, so it could not be used for validation. Sassi et al.48 observed this
variant in 6 out of 332 AD cases (1.8% of cases), and this variant had a
strong effect size (odds ratio= 6.19, 95% confidence interval= 1.099–
63.091). It was also observed in two of their 676 cognitive-normal con-
trol samples (0.30% of controls). TTR is known to be involved in amy-
loid beta (Aβ) catabolism and has no homologous proteins, suggest-
ing that subtle changes to this protein could have strong functional
implications.48 This analysis of high-risk cousin pairs adds additional
support to TTR as a gene that impacts AD.
Patel et al.49 reported missense mutations NM_000435.3:
c.743G > C (rs141402160) and NM_000435:c.593C > T
(rs140914494) in NOTCH3 using the pedigrees from this analysis
combined with other population resources. However, these variants
were not sequenced in the validationdatasets.NOTCH3plays a key role
in neural development and is known to cause cerebral autosomal dom-
inant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL). The same region of NOTCH3 was also linked to AD in a
Turkish family.14. NOTCH3 is known to bind PSEN150,51 and PSEN2.50
Furthermore, NOTCH3 had a P-value of 1 × 10−4 from the gene-based
testing of AD risk in the ADGC dataset, implying that multiple variants
in the genemay play a role in AD risk.
Two variants approached significance for increased AD risk in
the Knight ADRC CSF dataset. A missense mutation in PELI3
(NM_001243135.1:c.115G > C; rs148294193) has a suggestive pos-
itive influence on AD risk (P-value = .0553). PELI3 binds UBC52 and
APP.53 UBC is significantly downregulated in AD brains suggesting that
decreased UBC function may be important in AD pathogenesis includ-
ing increased neuronal death and non-regulated APP production.54
APP is awell-studied AD risk gene, andmanymutations in this gene are
known to cause early-onset AD. APP is cleaved into Aβ peptides, which
are a major component of the amyloid plaques deposited in the brains
of AD patients.55 PELI3 encodes a scaffold protein and an intermediate
signaling protein in the innate immune response pathway. Segregation
of the PELI3 variant to an additional AD-affected relative in the original
high-risk pedigree was observed.
AmissensemutationNM_001161357.1:c.557G>A (rs147599881)
in FCHO1 has an AD risk P-value of .0624 in the CSF with a
positive direction. FCHO1 also binds UBC56 and APP.53 FCHO1 is
involved in vesicle-mediated transportation and clathrin-mediated
endocytosis.
Three variants were not present in the Wellderly dataset and were
more prevalent in ADGC cases than ADGC controls. Missense vari-
ant NM_00124279.1:c.2113C > T (rs61729902) is located in SNAP91,
which encodes a protein that binds UBC.57 SNAP91 is involved in
vesicle-mediated transportation and clathrin-mediated endocytosis.
SNAP91 is a paralog of PICALM, a known top 10 AD risk gene,58
and they both have similarities between their functions of clathrin-
mediated endocytosis. The SNAP91 variant was observed in an addi-
tional AD case in the original high-risk pedigree sequenced.
Another missense mutation, NM_005205.3:c.34T > G
(rs140129800), was found in the COX6A2 gene, which encodes a
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protein that binds APP.53 COX6A2 is a terminal enzyme in the mito-
chondrial respiratory chain and is part of the Kyoto Encyclopedia of
Genes and Genomes (KEGG) pathway for AD.59–61
Missense mutation NM_024690.2:c.10900C > T (rs191804178)
in MUC16 affects binding of UBC,62 and MUC16 forms a protec-
tive mucous barrier on the apical surfaces of the epithelia. Muta-
tions in MUC16 are associated with ovarian cancer, endometriosis,
Pseudo-Meigs syndrome, serous cystadenocarcinoma, and bron-
chogenic cysts.MUC16 has not previously been implicated in AD.
4.1 Variants observed in more than one
AD-affected cousin pair
Three variants were observed to be shared by both members of the
AD-affected cousin pair in more than one high-risk pedigree. Mis-
sense variant NM_145886.3:c.2044C > T (rs200290640) and splice
site variant NM_145886.3:c.2042-2A > G (rs199752248) both affect
the PIDD1 gene, which is shown to bind APOE ε4.63 Neither of these
variants were sequenced in the ADGC validation datasets. PIDD1 con-
tains a death domain, interacts with other death domain proteins, and
is suggested to be an effector of p53-dependent apoptosis. Mutations
in PIDD1 are associated with poikiloderma with neutropenia (PN) dis-
order that affects the skin and the immune system.
4.2 Strengths and limitations
Rare variant-sharing in AD-affected relatives who are members of
validated high-risk pedigrees is central to prioritize candidate vari-
ants. Similar approaches capitalizing on shared genetics between
related individuals in high-risk pedigrees have been used successfully
in Utah for decades to identify rare variants contributing to common
diseases,10,64,65 as well as more recent adaptations.12,66 This study
design is limited by a relatively small available sample size (19 pedi-
grees with 38 index cases), the absence of other ethnicities besides
Whites, and the fact that AD phenotyping was based solely on death
certificate data. However, the approach raises statistical power by
increasing the relative allele frequencies of rare variants, which allows
a single pedigree in the sample set to identify rare candidate variants,
a key advantage in the presence of locus heterogeneity. Replication in
external datasets can be difficult to achieve, given the rare nature of
such variants. However, the absence of these limitations in external
dataset validations (i.e., if all variants were present in ADGC, Knight
ADRC, or the Wellderly dataset) would likely lead to more candidate
variants identified through this approach. The prioritization criteria
were very conservative and report only the most supported variants
that likely affect AD within these high-risk pedigrees. Additional vari-
ants that may affect AD within these pedigrees may have been de-
prioritized because of the stringent nature of the analysis. All genetic
variants identified at each prioritization level are reported for future
research to assess the relative support of each variant. The most sup-
ported variants were also assessed for co-segregation using a small
number of additional AD-affected relatives with the AD phenotype
within the original high-risk pedigrees. Although the UPDB popula-
tion genealogy data include the possibility of undocumented relation-
ships among subjects and inadequate phenotyping strategies, previous
research shows that founder effects and inbreeding are no greater in
the UPDB than in the general population,17,18 and the UPDB has been
used extensively in previous disease studies.
4.3 Conclusion
The presence of rare variants identified here may explain the preva-
lence of AD mortality in 19 of the 36 AD-affected individuals from
high-risk pedigrees (see Table S2). The excess AD mortality observed
in the remaining individuals might be due to complex interactions, het-
erogeneity in the pedigree, misdiagnosis of AD, non-coding variants,
or variants that were removed due to stringent prioritization crite-
ria. Because the initial prioritization included only variants in genes
known or predicted to affect AD pathology, the analysis is dependent
on current understanding of AD pathology and may not encompass
all disease-causing variants. However, the purpose of this study was
to identify highly supported candidate variants associated with AD
risk. To that end, these analyses provide additional support to previ-
ous studies that implicate ABCA7 and TTR with AD mortality. Because
many known AD risk variants were prioritized in these analyses, other
prioritized variants also likely affect AD mortality, and all 11 variants
spanning 9 genes should be prioritized in future analyses. These out-
comes indicate that a high-risk pedigree approach can achieve suffi-
cient power to detect rare variants, particularly when coupled with
external datasets that contain meaningful data about disease risk.
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